Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT01874756
Show Display Options
Rank Status Study
1 Recruiting The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: LY500307 150mg;   Drug: LY500307 75mg;   Drug: Placebo

Indicates status has not been verified in more than two years